Granules India share price will remain in focus on November 3 following the company posted better earnings for the quarter ended September 2026 (Q2FY17).
The company had reported a 39.2% year-on-year increase in net profit to Rs 182 crore in Q2, compared with Rs 131 crore a year ago.
Revenue of the company rose 20.3% to Rs 1,560 crore from Rs 1,297 crore, while EBITDA increased 21.3% to Rs 337.4 crore from Rs 278.1 crore.
EBITDA margin improved to 21.6% from 21.4% in the year-ago period.
The USFDA was conducted a current Good Manufacturing Practice inspection from October 19 to October 30, 2026, at finished dosage facility at Gagillapur, Hyderabad. and concluded with the issuance of a Form FDA 483 containing eleven observations.